Q3 Asset Management Summit Therapeutics Inc. Call Options Transaction History
Q3 Asset Management
- $161 Million
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SMMT
# of Institutions
211Shares Held
76.5MCall Options Held
2MPut Options Held
2.83M-
Baker Bros. Advisors LP New York, NY24.4MShares$491 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$220 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$159 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$109 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$69.8 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.05B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...